Maxitrol

Neomycin sulfate, Polymyxin B sulfate and Dexamethasone, the active ingredients in Maxitrol, are an antibiotic corticosteroid combination presented as a 3%/0.1%/0.5% ophthalmic suspension for ocular (topical) use. It treats bacterial conjunctivitis, keratitis and postoperative ocular inflammation in patients who need both antimicrobial and anti‑inflammatory therapy.

GNH USA supplies Maxitrol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxitrol is indicated for bacterial eye infections and inflammatory conditions of the ocular surface. - Bacterial conjunctivitis: reduces bacterial load and inflammation, promoting rapid resolution of infection. - Keratitis: provides antimicrobial coverage while suppressing corneal inflammation. - Post‑operative ocular inflammation: controls inflammation and prevents infection after eye surgery. - General ocular inflammation: alleviates swelling, redness and discomfort associated with non‑infectious inflammatory eye disorders.

Adverse reactions may occur with ocular use of Maxitrol.

Common Side Effects: - Burning or stinging sensation at the application site. - Transient blurred vision after instillation. - Mild eye itching or discomfort. - Temporary increase in intra‑ocular pressure. - Redness of the conjunctiva. - Mild tearing.

Serious or Rare Side Effects: - Allergic reactions such as angioedema, urticaria or severe eye irritation. - Secondary ocular infection or corneal ulceration. - Significant rise in intra‑ocular pressure leading to glaucoma. - Systemic corticosteroid effects with prolonged use, including adrenal suppression. - Vision loss due to severe inflammation or infection.

Use Maxitrol only under professional supervision and observe the following precautions. - Pregnancy: safety not established; prescribe only if potential benefit outweighs risk. - Breastfeeding: unknown excretion; consider risk to infant before use. - Contact lens wear: discontinue lenses while applying the drops and until irritation resolves. - Pre‑existing glaucoma or ocular hypertension: monitor intra‑ocular pressure closely. - Prolonged therapy: limit duration to reduce risk of steroid‑related complications. - Store at room temperature: keep in original container, protect from light and moisture.

Maxitrol may interact with other ophthalmic agents; consider the following.

Major Interactions (Avoid): - Systemic corticosteroids: may increase systemic steroid exposure and related adverse effects. - Concurrent use of other ophthalmic antibiotics: risk of antagonistic activity or additive toxicity. - Anticholinergic eye drops: may reduce ocular absorption of Maxitrol.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory eye drops: may potentiate intra‑ocular pressure elevation. - Glaucoma medications: monitor pressure as Maxitrol can counteract pressure‑lowering effects. - Preservative‑containing contact lens solutions: may increase ocular irritation when used together.